A drug candidate dubbed Aes-103 that was developed by researchers at the US National Institute of Health's National Center for Advancing Translational Sciences has been acquired by Baxter International's BioScience business.

According to NIH, Aes-103 was developed to target the underlying molecular mechanism of sickle cell disease, and Baxter will now usher the drug through the next stages of clinical development with an eye toward obtaining regulatory approval and commercializing the drug.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.